Literature DB >> 23624062

Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

J L Scavone1, R C Sterling, E J Van Bockstaele.   

Abstract

Withdrawal from opiates, such as heroin or oral narcotics, is characterized by a host of aversive physical and emotional symptoms. High rates of relapse and limited treatment success rates for opiate addiction have prompted a search for new approaches. For many opiate addicts, achieving abstinence may be further complicated by poly-drug use and co-morbid mental disorders. Research over the past decade has shed light on the influence of endocannabinoids (ECs) on the opioid system. Evidence from both animal and clinical studies point toward an interaction between these two systems, and suggest that targeting the EC system may provide novel interventions for managing opiate dependence and withdrawal. This review will summarize the literature surrounding the molecular effects of cannabinoids and opioids on the locus coeruleus-norepinephrine system, a key circuit implicated in the negative sequelae of opiate addiction. A consideration of the trends and effects of marijuana use in those seeking treatment to abstain from opiates in the clinical setting will also be presented. In summary, the present review details how cannabinoid-opioid interactions may inform novel interventions in the management of opiate dependence and withdrawal.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-AG; 2-arachidonoylglycerol; AC; CB1r; CREB; CRF; EC; HPA; LC; MMT; MOR; NAc; NTS; PGi; PKA; UDS; adenylyl cyclase; cAMP response element binding protein; cannabinoid type 1 receptors; clinical; corticotropin releasing factor; endocannabinoid; hypothalamic–pituitary–adrenal; locus coeruleus; marijuana; methadone maintenance treatment; mu-opioid receptor; norepinephrine; nucleus accumbens; nucleus of the solitary tract; paragigantocellularis; protein kinase-A; stress; urinary drug screen

Mesh:

Substances:

Year:  2013        PMID: 23624062      PMCID: PMC3742578          DOI: 10.1016/j.neuroscience.2013.04.034

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  248 in total

Review 1.  An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.

Authors:  Liana Fattore; M Sabrina Spano; Serena Deiana; Valeria Melis; Gregorio Cossu; Paola Fadda; Walter Fratta
Journal:  Brain Res Rev       Date:  2006-07-12

2.  Repeated cannabinoid administration increases indices of noradrenergic activity in rats.

Authors:  M E Page; V C Oropeza; S E Sparks; Y Qian; A S Menko; E J Van Bockstaele
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

3.  Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

Authors:  Sabine Steffens; Niels R Veillard; Claire Arnaud; Graziano Pelli; Fabienne Burger; Christian Staub; Meliha Karsak; Andreas Zimmer; Jean-Louis Frossard; François Mach
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

4.  Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. II. Adaptation to chronically presented stressful stimuli.

Authors:  E D Abercrombie; B L Jacobs
Journal:  J Neurosci       Date:  1987-09       Impact factor: 6.167

5.  Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.

Authors:  Diana L Cichewicz; Erin A McCarthy
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

Review 6.  Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two.

Authors:  Peter J Cohen
Journal:  J Pain Palliat Care Pharmacother       Date:  2009

Review 7.  Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.

Authors:  F C Machado Rocha; S C Stéfano; R De Cássia Haiek; L M Q Rosa Oliveira; D X Da Silveira
Journal:  Eur J Cancer Care (Engl)       Date:  2008-07-09       Impact factor: 2.520

8.  mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization.

Authors:  Veronica A Alvarez; Seksiri Arttamangkul; Vu Dang; Abdallah Salem; Jennifer L Whistler; Mark Von Zastrow; David K Grandy; John T Williams
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

Review 9.  Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications.

Authors:  Emmanuel S Onaivi
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 10.  Neurobiological mechanisms of cannabinoid addiction.

Authors:  L Fattore; P Fadda; M S Spano; M Pistis; W Fratta
Journal:  Mol Cell Endocrinol       Date:  2008-02-16       Impact factor: 4.102

View more
  61 in total

1.  Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

Authors:  Marcus A Bachhuber; Brendan Saloner; Chinazo O Cunningham; Colleen L Barry
Journal:  JAMA Intern Med       Date:  2014-10       Impact factor: 21.873

2.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 3.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

4.  No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper.

Authors:  David H Epstein; Kenzie L Preston
Journal:  Am J Addict       Date:  2015-04-06

Review 5.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

6.  Why Marijuana Will Not Fix the Opioid Epidemic.

Authors:  Kenneth Finn
Journal:  Mo Med       Date:  2018 May-Jun

7.  High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.

Authors:  Maria Eugenia Socías; Evan Wood; Stephanie Lake; Seonaid Nolan; Nadia Fairbairn; Kanna Hayashi; Hennady P Shulha; Seagle Liu; Thomas Kerr; M-J Milloy
Journal:  Addiction       Date:  2018-09-20       Impact factor: 6.526

8.  Safety of oral dronabinol during opioid withdrawal in humans.

Authors:  Crystal J Jicha; Michelle R Lofwall; Paul A Nuzzo; Shanna Babalonis; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

9.  Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children.

Authors:  Vidya Chidambaran; Valentina Pilipenko; Kristie Spruance; Raja Venkatasubramanian; Jing Niu; Tsuyoshi Fukuda; Tomoyuki Mizuno; Kejian Zhang; Kenneth Kaufman; Alexander A Vinks; Lisa J Martin; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2016-12-15       Impact factor: 2.533

10.  Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy.

Authors:  Jacek Biesiada; Vidya Chidambaran; Michael Wagner; Xue Zhang; Lisa J Martin; Jaroslaw Meller; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.